Werewolf Therapeutics Presents Cancer Drug Research in Arizona
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Werewolf Therapeutics, Inc. announced it will present research findings at the Society for Immunotherapy of Cancer’s 2026 Annual Meeting in Phoenix, Arizona. The company will present an oral abstract detailing a Phase 1/1b study of the prodrug WTX-124, and a poster on a Phase 1b/2 study of the prodrug WTX-330. These studies examine the drugs for treating solid tumors in adults with relapsed or refractory disease.
From manilatimes.net
Why it matters
The presentation details the progress of two clinical trials for cancer therapeutics. The results of these Phase 1 and Phase 1/2 studies could influence the market valuation and future commercial viability of Werewolf Therapeutics.
From manilatimes.net
Who's involved
- ArizonaLocation where the annual meeting is being held.